RACHEL MCADAMS: Open Payments
NPI 1528244472 · HAMPTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 14 payments from 8 companies in 2025. Trend: 2023 $730 · 2024 $494 · 2025 $447
Food & beverage: $357Education: $90
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 4 | $166 |
| Astellas Pharma US Inc | 3 | $138 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Exeltis, USA Inc. | 1 | $22 |
| Biogen, Inc. | 1 | $22 |
| CooperSurgical, Inc. | 1 | $16 |
Products named: GEMTESA, Veozah, ZEPBOUND, SLYND, ZURZUVAE, Mirena, Lynkuet, Paragard T 380A.
Industry payments across VA — which companies pay providers there.
